About: Outer Membrane Protein, Oma87 Prevents Acinetobacter baumannii Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outer Membrane Protein, Oma87 Prevents Acinetobacter baumannii Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outer Membrane Protein, Oma87 Prevents Acinetobacter baumannii Infection
Creator	Abdolhamidi, Raziyeh Astaneh, Alipour Darvish, Shakiba Jahangiri, · Rasooli, Iraj
Source	PMC
abstract	Acinetobacter baumannii is one of the most problematic pathogens in clinical settings. Emerging of its antibiotic-resistant strains persuade researchers to find alternative treatment options such as immunization against the notorious nosocomial pathogen. Oma87 has been introduced as an immunogenic outer membrane protein via reverse vaccinology. However, protectivity of A. baumannii Oma87 is not well known. The current research undertakes a study on the immunogenicity of recombinant Oma87 in a murine model. Some physico-chemical properties were assessed via in silico analyses. The corresponding gene was amplified and cloned into pET28a plasmid. The recombinant protein was purified and then was administered to immunize mice. Sera obtained from the immunized mice were assessed with respect to the triggered antibodies. Challenges were performed on actively or passively immunized mice. In silico analyses revealed that this protein is the same as BamA. A high titer of specific antibody was raised against rOma87 even after the first injection. The specific antibody recognized the whole cell of A. baumannii. Both active and passive immunizations confer 100 and 50% protection, respectively against ~ 2 × lethal dose (LD) of A. baumannii in the murine sepsis model. Although none of mice received ~ 5 × LD of A. baumannii survived in passive immunization, 25% of mice challenged with ~ 7 × LD of the bacteria survived and the dead mice exhibited a delayed death. Based on these results, Oma87 is the same as BamA which could be considered as a promising vaccine candidate against A. baumannii in the sepsis model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10989-020-10056-0) contains supplementary material, which is available to authorized users.
has issue date	2020-03-09(xsd:dateTime)
bibo:doi	10.1007/s10989-020-10056-0
bibo:pmid	32421073
has license	no-cc
sha1sum (hex)	5865c70cb59da58cb20e531e60f2b54e1f657f65
schema:url	https://doi.org/10.1007/s10989-020-10056-0
resource representing a document's title	Outer Membrane Protein, Oma87 Prevents Acinetobacter baumannii Infection
has PubMed Central identifier	PMC7223757
has PubMed identifier	32421073
schema:publication	Int J Pept Res Ther
resource representing a document's body	covid:5865c70cb59da58cb20e531e60f2b54e1f657f65#body_text
is schema:about of	named entity 'BamA' named entity 'bacteria' named entity 'respect' named entity 'Sera' named entity 'vaccine' named entity 'pathogen' named entity 'murine' named entity 'lethal dose' named entity 'Protein' named entity 'MODEL' named entity 'NOT WELL' named entity 'BASED' named entity 'IMMUNIZED' named entity 'RECEIVED' named entity 'VACCINE CANDIDATE' named entity 'INJECTION' named entity 'PROTECTION' named entity 'CURRENT' named entity 'HIGH' named entity 'CHEMICAL PROPERTIES' named entity 'TITER' named entity 'SERA' named entity 'CLINICAL SETTINGS' named entity 'ALTERNATIVE' named entity 'AMPLIFIED' named entity 'antibodies' named entity 'dead' named entity 'BamA' named entity 'Challenges' named entity 'high' named entity 'Emerging' named entity 'pathogens' named entity 'plasmid' named entity 'current research' named entity 'A. baumannii' named entity 'mice' named entity 'antibiotic-resistant' named entity 'mice' named entity 'mice' named entity 'Acinetobacter baumannii' named entity 'alternative treatment' named entity 'passive immunization' named entity 'protein' named entity 'Infection' named entity 'antigenic' named entity 'antigens' named entity 'Refolding' named entity 'outer membrane protein' named entity '450 nm' named entity 'molecular weight' named entity 'pathogen' named entity 'IgG' named entity 'antigen' named entity 'passive immunization' named entity '37 °C' named entity 'protein' named entity 'drug resistant' named entity 'A. baumannii' named entity 'structure of proteins' named entity 'standard conditions' named entity 'protein' named entity 'protein' named entity 'absorbance' named entity 'membrane protein' named entity 'protein sequence' named entity 'half-life' named entity 'reverse vaccinology' named entity 'antibiotic' named entity 'signal peptide' named entity 'antigen' named entity 'aliphatic' named entity 'aliphatic' named entity 'active immunization' named entity 'immunocompromised patients' named entity 'thrice' named entity 'transformed cells' named entity 'mucosal immunity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software